Business Wire

European Patent For Puustelli Miinus Furniture

Del

Puustelli Group Oy has been granted a European patent for Miinus furniture system inventions. The furniture parts and particularly the structures of the cabinet carcass include many patented details. The Miinus invention is the most important innovation in the global furniture industry for decades. Recyclable biocomposite has replaced the MDF and chipboard traditionally widely used as carcass materials in furniture. The raw material is made in Finland and consists of a polypropylene and pulp fibre compound. The side components of the patented structure are made by injection moulding. Whereas the invention allows for various types and sizes of frame parts to be made, each part requires a separate mould. The colours of the moulded parts can be flexibly varied. Thanks to the injection moulding method and choice of material, the components have excellent precision and strength, as well as excellent moisture resistance. Besides which, material waste is minimal.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190203005007/en/

Puustelli Group Oy has been granted a European patent for Miinus furniture system inventions. The fu ...

Puustelli Group Oy has been granted a European patent for Miinus furniture system inventions. The furniture parts and particularly the structures of the cabinet carcass include many patented details. Photo: Puustelli

Biocomposite frame receives excellent indoor air and durability test results
The material releases no toxic emissions into the indoor air and retains its dimensional stability, strength and colours also in highly challenging conditions.

  • 0% formaldehyde content
  • anti-static material
  • soaking in water for several months / no changes
  • stress test carried out using 350 kg weights for months / no changes in shape
  • temperature fluctuations / -25Co and + 90Co / no changes
  • colour resistance during tests / no changes
  • excellent screw grip and re-fastening

Modifiable biocomposite carcasses are unusual
Holes to join the carcasses and to fasten hinges, mechanisms and drawer sliders have been ready made in conjunction with mould injection of the frame. Biocomposite is not subject to fatigue and the structures have excellent modifiability. For example, a cabinet can be transformed into drawers and the other way around without completely removing the carcass. Since the holes have been ready made, fastening the screws couldn’t be easier when making changes. The parts remain firmly in place in a Miinus carcass far better than in traditional chipboard. And unlike a chipboard carcass, the Miinus carcass can withstand being removed, transferred and re-fastening numerous times.

About the materials
With the Miinus kitchen all unnecessary material has been removed, minused. The kitchen’s weight (mass) is about half that of a comparable kitchen. This makes it lighter to handle, install and transport. Which is also why the carbon footprint originating in transport is almost half that of a typical kitchen. Recyclability, carbon footprint calculations and a number of research findings prove that familiar materials such as MDF or chipboard, melamine or laminate surfaces cannot be used in an ecological kitchen.

All in all, a Miinus kitchen undercuts the best indoor air ratings by as much as half, depending on the choice of material and surface treatments.

Inspiration for the Miinus kitchen
“Development was inspired by our wish to take concrete action for the good of the environment. The goal was to reduce the carbon footprint originating in kitchen manufacturing and to lower the environmental burden throughout the kitchen’s lifecycle. Our mission took on greater importance with the growing demand for ecological alternatives. Our patented Miinus kitchen has now been found to respond to this demand,” says Puustelli Group’s CEO Jussi Aine.

Development work took years
There was no research data available for development work since no extensive objective research on materials had been done anywhere else. Development work took years because each solution had to be tested before the injection moulded Miinus biocomposite carcass solution was fully ready for use and goals were reached. Along the way, Puustelli’s development team required numerous researchers specialised in different technologies as well as the know-how, tests, prototypes and 3D models of many parties.

Image and video link information attached.

About Puustelli Group Oy

Puustelli Group Oy is part of Harjavalta Group, a Finnish family enterprise. The Group also includes Kastelli Group Oy and Lapti Group Oy. In 2017, Harjavalta Group had around 1,100 permanent employees and turnover of around €386 million.

The ecological Miinus kitchen has been produced by Puustelli since 2013 and is sold in Finland, Sweden, the UK and USA. Project sales account for a significant share.

Contact information

Pirjo Leva, executive secretary
Puustelli Group Oy
tel. +358 10 277 6218
pirjo.leva@puustelli.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Telna Launches New eSIM Solution at MWC Barcelona 201924.2.2019 00:00:00Pressemelding

Telna, a vertically integrated Network-as-a-Service (NaaS) provider of global end-to-end connectivity solutions, today is adding eSIM technology to its platform. The new resilient and efficient eSIM architecture will be showcased at Mobile World Congress Barcelona 2019, from February 25th - February 28th at Telna’s booth in Hall 1, Stand 1B80. “eSIM technology is another example of a global trend in digital transformation set to disrupt cellular connectivity,” says Gregory Gundelfinger, CEO of Telna. “Our customers now have access to both Consumer and IoT/M2M eSIM that is bundled with the rest of our software-defined network services.” eSIM is an embedded SIM card, meaning there is no physical SIM card and no physical swapping of SIM cards. It's easy to add data plans and is endorsed by the GSMA. “The virtualization of the SIM card removes one of the largest barriers when switching between networks, the physical SIM card,” says Gundelfinger. The Telna eSIM allows users to access their

Hilton Launches New Brand, Signia Hilton, Delivering Sophisticated Travel While Reimagining Meetings and Events22.2.2019 17:00:00Pressemelding

Hilton (NYSE: HLT) today announced the launch of Signia Hilton, its dynamic, new meetings-and-events-focused brand. The portfolio of hotels is setting out to transform the industry for meeting professionals and sophisticated business travelers by infusing state-of-the-art technology and design into every aspect of the guest experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005071/en/ The brand further reinforces Hilton’s commitment to innovation that meets the evolving needs of today’s travelers and will bring premium experiences to top urban and resort destinations around the world. “In our 100th year of hospitality, we are more focused than ever on providing exceptional experiences to all of our guests – and that includes evolving those experiences to meet their changing needs,” said Christopher J. Nassetta, president and CEO, Hilton. “We are proud to launch Signia Hilton, which exemplifies our innovative sp

Axonics® Granted Expanded CE Mark Label; First and Only Sacral Neuromodulation System Approved for Use with Full-Body MRI Scans22.2.2019 16:30:00Pressemelding

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today that it has received CE mark approval for 1.5T and 3T full-body magnetic resonance imaging (“MRI”) conditional labeling for the Axonics r-SNM® System. The Axonics r-SNM System is the only implantable SNM system that has received full-body MRI conditional labeling for sale in Europe1. Raymond W. Cohen, Chief Executive Officer of Axonics, said, “Without this labeling, any patient requiring an MRI scan on any body part below the head must have their neurostimulator surgically explanted prior to the MRI scan, resulting in an additional surgery for the patient and additional costs to patients and the healthcare system. This authorization of full-body MRI scans in Europe is another important milestone for Axonics, differentiating our te

Fantastec Joins Forces with Arsenal FC Launching Official Blockchain Collectibles App22.2.2019 14:30:00Pressemelding

Fantastec announced today its first football licensing agreement with Premier League club Arsenal FC for a new blockchain authenticated collectibles app called Fantastec SWAP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005277/en/ Arsenal players appear on Fantastec SWAP in official licensing deal (Graphic: Business Wire) London-based Fantastec is a leading sports fan technology innovator, and its blockchain based ‘SWAP’ app will have broad appeal to global sports fans, gamers and sports card collectors alike. Fantastec SWAP unlocks unique and authentic club content through the app, like player autographs and exclusive footage. With its innovative blockchain technology, fans around the world can now discover, collect and swap officially licensed club collectibles with other fans with complete trust. “Fantastec SWAP is a game-changer for international football fans as well the sports collectibles industry,” commented

Volkswagen Protects Virtual Key Sharing App with Trustonic Application Protection22.2.2019 13:42:00Pressemelding

Volkswagen is working with mobile cyber security leader Trustonic to enable customers to use smartphones to access their vehicles, and to securely share their digital car keys to grant access to others via a smartphone app. Volkswagen is using the Trustonic Application Protection (TAP) platform to secure the mobile app and ensure that sensitive information and key transfer requests are securely displayed to, and approved by, a real authenticated user on a trusted device and not by hackers or malware simulating a user or device. “The smartphone is becoming the vehicle key of the future and our We Connect service is the interface for this today in the new Volkswagen Passat,” comments Alf Pollex, Head of Infotainment and Connected Car at Volkswagen AG. “The user installs the We Connect app on their smartphone which is then authorized via the infotainment system with a Transaction Number. The Mobile Key will be compatible with Android-based Samsung devices. No mobile network connection is

Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for etoposide toniribate in relapsed/refractory biliary tract cancer22.2.2019 13:30:00Pressemelding

Mundipharma EDO GmbH, part of the Mundipharma network of independent associated companies, and Imbrium Therapeutics L.P., an operating subsidiary of Purdue Pharma L.P., today announced that the US FDA has granted Orphan Drug Designation (ODD) to etoposide toniribate for the treatment of relapsed/refractory biliary tract cancer, also known as cholangiocarcinoma.3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005126/en/ Biliary tract cancer is a rare tumour with approximately 8,000 patients diagnosed in the US every year and 10,571 in Europe.4,5 The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US. Radical surgery is the only curative treatment for biliary tract cancer but, in most cases, the cancer is inoperable. Patients who fail first-line chemotherapy have limited treatment options and the standard of